Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822989 · ClinicalTrials.gov registry record · NA
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02822989 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 19 participants.
The verdict
NCT02822989, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms. This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain. This study will additionally investigate the biologic effects of vagus nerve stimulation on inflammation. It will be the first clinical study using one of the body's own pathways of modulating the immune system and inflammatory response, the cholinergic anti-inflammatory pathway, in SLE.
Interventions
- DEVICE Vagus nerve stimulation
- DEVICE Sham vagus nerve stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2020-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822989
The ClinicalTrials.gov registry entry for NCT02822989 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vagus nerve stimulation is the first listed.
NCT02822989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02822989 about?
NCT02822989 is a clinical study titled "Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain". Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms. This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain. This study will additionally inves...
What is the current status of trial NCT02822989?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2017-11-01. Estimated completion is 2020-11-01.
What interventions are being tested in trial NCT02822989?
The interventions under investigation include: Vagus nerve stimulation (DEVICE), Sham vagus nerve stimulation (DEVICE).
Who is sponsoring clinical trial NCT02822989?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.